Tuesday, September 19, 2017
 
 
Company News: Page (1) of 1 - 09/08/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Pulmatrix to Present at the Rodman & Renshaw Global Investment Conference on September 11, 2017
 
(September 08, 2017)

LEXINGTON, Mass., Sept. 8, 2017 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 10:25 AM EDT in the Lotte New York Palace Hotel in New York City. As part of the presentation, William Duke, Jr., Chief Financial Officer for Pulmatrix, will provide an update on the Company's business and its pipeline of inhaled therapeutics.

Pulmatrix logo (PRNewsFoto/Pulmatrix, Inc.)

The presentation will highlight Pulmatrix's recent in-licensing of narrow spectrum kinase inhibitors (NSKI) from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc., and provide updates on the lead pipeline programs.


About Pulmatrix  
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF) and severe asthma, and PUR1800, a narrow spectrum kinase inhibitor for patients with COPD. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for COPD.  Pulmatrix's product candidates are based on iSPERSE, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

FORWARD-LOOKING STATEMENTS
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 10, 2017, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact                                           


Robert Clarke, CEO                                        

William Duke, CFO    

(781) 357-2333                                                          

(781) 357-2333          

[email protected]                                

[email protected]

 

View original content with multimedia:http://www.prnewswire.com/news-releases/pulmatrix-to-present-at-the-rodman--renshaw-global-investment-conference-on-september-11-2017-300515971.html

SOURCE Pulmatrix, Inc.

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords: Inc., Disease, Surgery, Children, Science, Medical, Biology, Business, Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines